Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Mirum Pharmaceuticals Inc (NQ: MIRM ) 39.38 -0.75 (-1.87%) Streaming Delayed Price Updated: 4:00 PM EDT, Aug 2, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Mirum Pharmaceuticals Inc < Previous 1 2 3 4 5 6 7 8 9 Next > Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) March 10, 2023 From Mirum Pharmaceuticals, Inc. Via Business Wire Mirum Pharmaceuticals Earnings Perspective: Return On Capital Employed March 10, 2023 Via Benzinga Analyst Expectations for Mirum Pharmaceuticals's Future March 09, 2023 Via Benzinga Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Business Update March 08, 2023 From Mirum Pharmaceuticals, Inc. Via Business Wire Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End 2022 Financial Results and Host Conference Call on March 8, 2023 March 01, 2023 From Mirum Pharmaceuticals, Inc. Via Business Wire Mirum Pharmaceuticals's Return On Capital Employed Insights December 14, 2022 Via Benzinga Europe Approves Mirum Pharma's Drug For Rare Genetic Liver Disease December 13, 2022 Via Benzinga Where Mirum Pharmaceuticals Stands With Analysts November 10, 2022 Within the last quarter, Mirum Pharmaceuticals (NASDAQ:MIRM) has observed the following analyst ratings: Via Benzinga Earnings Scheduled For March 8, 2023 March 08, 2023 Companies Reporting Before The Bell • Daktronics (NASDAQ:DAKT) is expected to report quarterly earnings at $0.00 per share on revenue of $164.68 million. Via Benzinga Earnings Preview: Mirum Pharmaceuticals March 07, 2023 Via Benzinga Mirum Pharmaceuticals Submits Supplemental New Drug Application to FDA for LIVMARLI in Patients with Cholestatic Pruritus in Progressive Familial Intrahepatic Cholestasis February 14, 2023 From Mirum Pharmaceuticals, Inc. Via Business Wire Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) February 10, 2023 From Mirum Pharmaceuticals, Inc. Via Business Wire Mirum Pharmaceuticals to Participate in SVB Securities Global Biopharma Conference February 09, 2023 From Mirum Pharmaceuticals, Inc. Via Business Wire Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) January 10, 2023 From Mirum Pharmaceuticals, Inc. Via Business Wire AT&T To Rally Over 15%? Here Are 10 Other Analyst Forecasts For Tuesday January 10, 2023 Keybanc boosted Five Below, Inc. (NASDAQ: FIVE) price target from $188 to $200. Keybanc analyst Bradley Thomas maintained an Overweight rating on the stock. Five Below shares fell 1.6% to $183.92 in... Via Benzinga Mirum Pharmaceuticals Announces Preliminary Unaudited LIVMARLI 2022 Net Revenue and Provides Corporate Updates January 09, 2023 From Mirum Pharmaceuticals, Inc. Via Business Wire Mirum Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023 January 03, 2023 From Mirum Pharmaceuticals, Inc. Via Business Wire Mirum Pharmaceuticals Appoints Lon Cardon to Board of Directors December 19, 2022 From Mirum Pharmaceuticals, Inc. Via Business Wire Mirum Pharmaceuticals’ LIVMARLI (maralixibat) Approved by the European Commission for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome Two Months and Older December 13, 2022 From Mirum Pharmaceuticals, Inc. Via Business Wire Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) December 09, 2022 From Mirum Pharmaceuticals, Inc. Via Business Wire Mirum Pharmaceuticals Provides Development Program Updates November 29, 2022 From Mirum Pharmaceuticals, Inc. Via Business Wire Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences November 18, 2022 From Mirum Pharmaceuticals, Inc. Via Business Wire Robinhood, MicroStrategy And Other Big Losers From Wednesday November 10, 2022 U.S. stocks closed lower on Wednesday, with the Dow Jones dipping more than 600 points. Here is the list of some big stocks recording losses in the previous session. Via Benzinga Why Merrimack Pharmaceuticals Shares Jumped Around 213%; Here Are 114 Biggest Movers From Yesterday November 10, 2022 Gainers Via Benzinga Why RumbleON Shares Are Trading Higher By Around 28%? Here Are 84 Stocks Moving In Wednesday's Mid-Day Session November 09, 2022 Gainers Via Benzinga Mirum Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update November 09, 2022 From Mirum Pharmaceuticals, Inc. Via Business Wire Mirum Presents New Data from LIVMARLI Phase 3 PFIC Study and ALGS Infant Study in Late-Breaker Presentations at The Liver Meeting of AASLD November 07, 2022 From Mirum Pharmaceuticals, Inc. Via Business Wire Mirum Pharmaceuticals to Announce Third Quarter 2022 Financial Results and Host Conference Call on November 9, 2022 November 01, 2022 From Mirum Pharmaceuticals, Inc. Via Business Wire Mirum’s LIVMARLI Data Featured in Two Late-Breaker Presentations at The Liver Meeting of the American Association for the Study of Liver Diseases October 31, 2022 From Mirum Pharmaceuticals, Inc. Via Business Wire Why Taysha Gene Therapies Shares Jumped Over 97%; Here Are 70 Biggest Movers From Yesterday October 26, 2022 Gainers Taysha Gene Therapies, Inc. (NASDAQ: TSHA) surged 97.4% to close at $2.98 after Astellas Pharma Inc announced it will invest a total of $50 million to acquire 15% of the company. Via Benzinga < Previous 1 2 3 4 5 6 7 8 9 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.